Inhibrx Earnings Estimate

INBX -  USA Stock  

USD 39.91  0.09  0.23%

Many public companies, such as Inhibrx, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Inhibrx's earnings estimates, investors can diagnose different trends across Inhibrx's analyst sentiment over time as well as compare current estimates against different timeframes.
Inhibrx is projected to generate -2.31 in earnings per share on the 31st of December 2021. Inhibrx earnings estimates module stress-tests analyst consensus about projected Inhibrx EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Please see Risk vs Return Analysis.

Inhibrx Earnings Estimates 

 
Refresh
Gross Profit is likely to rise to about 13.5 M in 2021, whereas Profit Margin is likely to drop (6.37)  in 2021.

Inhibrx Earnings Estimation Breakdown

Calculation of earning per share of Inhibrx is based on official Zacks consensus of 1 analysts regarding Inhibrx future annual earnings. Given the historical accuracy of 63.64%, the future earnings per share of Inhibrx is estimated to be -2.31 with the lowest and highest values of -2.4 and -2.22, respectively. Please note that this consensus of annual earnings estimates for Inhibrx is an estimate of EPS before non-recurring items and including employee stock options expenses
Current EPS
0.0
19th of October 2021
-2.4
Lowest
Estimated EPS
-2.31
-2.22
Highest

Inhibrx Earnings Projection Consensus

Suppose the current estimates of Inhibrx's value are higher than the current market price of the Inhibrx stock. In this case, investors may conclude that Inhibrx is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Inhibrx's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

1

63.64%

0.0

-2.31

Inhibrx Earnings per Share Projection vs Actual

Actual Earning per Share of Inhibrx refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Inhibrx predict the company's earnings will be in the future. The higher the earnings per share of Inhibrx, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Inhibrx Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Inhibrx, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Inhibrx should always be considered in relation to other companies to make a more educated investment decision.

Inhibrx Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Inhibrx's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-09
2021-06-30-0.6-0.550.05
2021-05-13
2021-03-31-0.57-0.510.0610 
2021-03-12
2020-12-31-0.525-0.230.29556 
2020-11-13
2020-09-30-0.625-0.77-0.14523 
2020-08-19
2020-06-30None-0.4893None

About Inhibrx Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Inhibrx earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Inhibrx estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Inhibrx fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Accumulated Retained Earnings Deficit-145.4 M-149.2 M
Earning Before Interest and Taxes EBIT-65.3 M-70.5 M
Earnings per Basic Share(3.01) (3.25) 
Earnings per Diluted Share(3.01) (3.25) 
Price to Earnings Ratio(9.86) (10.64) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-62.9 M-67.9 M
Earnings before Tax-76.1 M-82.1 M
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California. Inhibrx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 84 people.

Inhibrx Investors Sentiment

The influence of Inhibrx's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Inhibrx. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - INBX

Inhibrx Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Inhibrx. What is your judgment towards investing in Inhibrx? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inhibrx using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Inhibrx information on this page should be used as a complementary analysis to other Inhibrx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Inhibrx Stock analysis

When running Inhibrx price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
The market value of Inhibrx is measured differently than its book value, which is the value of Inhibrx that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibrx's value that differs from its market value or its book value, called intrinsic value, which is Inhibrx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibrx's market value can be influenced by many factors that don't directly affect Inhibrx underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibrx's value and its price as these two are different measures arrived at by different means. Investors typically determine Inhibrx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibrx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.